# Seaport Therapeutics, Inc. (SPTX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/seaport-therapeutics-inc/ JSON: https://steadybase.io/company/seaport-therapeutics-inc.json Checked Nov 21, 2026. Latest filing read: Nov 2, 2026.

## Company

- Legal name: Seaport Therapeutics, Inc.
- Ticker: SPTX (Nasdaq)
- SEC CIK: 0002042347
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Boston, MA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Website: seaporttx.com
- Investor relations: https://investors.seaporttx.com/
- LinkedIn: https://www.linkedin.com/company/seaport-therapeutics
- Next earnings date: Dec 28, 2026

## Key facts

- Shares outstanding: 53,530,550 as of Oct 27, 2026 (10-Q filed Nov 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526442634/0001193125-26-442634-index.html

## Officers and directors

- Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics. LinkedIn: https://linkedin.com/in/daphnezohar. Source: 8-K filed Nov 2, 2026, https://www.sec.gov/Archives/edgar/data/2042347/000119312526442625/sptx-ex99_1.htm
- Lauren White, Chief Financial Officer. Source: Form 4 filed May 4, 2026, https://www.sec.gov/Archives/edgar/data/2042347/000119312526204493/0001193125-26-204493-index.htm
- Antony Loebel, Chief Medical Officer. LinkedIn: https://linkedin.com/in/antony-loebel. Source: Form 4 filed May 4, 2026, https://www.sec.gov/Archives/edgar/data/2042347/000119312526204452/0001193125-26-204452-index.htm
- Lana Gladstein, General Counsel. LinkedIn: https://linkedin.com/in/lana-gladstein-aa31674. Source: Form 4 filed May 4, 2026, https://www.sec.gov/Archives/edgar/data/2042347/000119312526204479/0001193125-26-204479-index.htm
- Michael Cunyuan Chen, Chief Scientific Officer. Source: Form 4 filed May 4, 2026, https://www.sec.gov/Archives/edgar/data/2042347/000119312526204471/0001193125-26-204471-index.htm

## Recent 8-K events

- Nov 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526442625/sptx-20261102.htm
- Aug 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-20260803.htm
- Jun 8, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/sptx-20260608.htm
- May 4, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526204086/d150068d8k.htm

## Insider trades (Form 4)

- Nov 3, 2026: Denice Torres (Director) bought 5,000 shares, about $99,325. Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526446216/0001193125-26-446216-index.htm
- Jun 22, 2026: Robert J. Hombach (Director) bought 13,000 shares, about $235,820. Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526280175/0001193125-26-280175-index.htm

## What management said

- "Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial" Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics (8-K filed Nov 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/2042347/000119312526442625/sptx-ex99_1.htm

## Latest filings

- 8-K filed Nov 2, 2026: https://www.sec.gov/Archives/edgar/data/2042347/000119312526442625/sptx-20261102.htm
- 10-Q filed Nov 2, 2026: https://www.sec.gov/Archives/edgar/data/2042347/000119312526442634/sptx-20260930.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

